ReviewDiscover oncology2025
CK2 in the spotlight: decoding its role in hematological malignancies and therapeutic applications.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CSNK2B Expression Aligns with a GDF15-Associated Immune Molecular State in Hepatocellular Carcinoma.Biomedicines · 2026Article
- Lineage-specific CK2α deletion reshapes the transcriptome of hematopoietic stem cells toward an immune-primed state.bioRxiv : the preprint server for biology · 2026Article
- A novel quinine derivative as a PIM-1 kinase inhibitor induces apoptosis via mitochondrial depolarization with selective cytotoxicity in acute lymphoblastic leukemia cells.Frontiers in pharmacology · 2026Article
- Pro-Apoptotic Activity of 1-(4,5,6,7-Tetrabromo-1International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Protein kinase CK2 is known to have potent biological effects, and its high expression is closely associated with malignant phenotypes of tumors, especially hematological malignancies. Targeting protein kinase CK2 is a promising therapeutic direction in hematological malignancies, as it promotes the survival of tumor cells and regulates the cell cycle and enhances the resistance of tumor cells to tumor therapy. In recent years, a large number of studies have confirmed the therapeutic effect of targeting protein kinase CK2 in combination with other therapies in the treatment of hematological malignancies. Here, we reviewed the key signaling pathways regulated by protein kinase CK2, the role of protein kinase CK2 in various hematological malignant tumors, the research progress and the potential clinical application prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.